217 related articles for article (PubMed ID: 19266525)
1. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds.
Peters JU; Schnider P; Mattei P; Kansy M
ChemMedChem; 2009 Apr; 4(4):680-6. PubMed ID: 19266525
[TBL] [Abstract][Full Text] [Related]
2. Can we discover pharmacological promiscuity early in the drug discovery process?
Peters JU; Hert J; Bissantz C; Hillebrecht A; Gerebtzoff G; Bendels S; Tillier F; Migeon J; Fischer H; Guba W; Kansy M
Drug Discov Today; 2012 Apr; 17(7-8):325-35. PubMed ID: 22269136
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the relationship between topology and selectivity for druglike molecules.
Yang Y; Chen H; Nilsson I; Muresan S; Engkvist O
J Med Chem; 2010 Nov; 53(21):7709-14. PubMed ID: 20942392
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
Price DA; Blagg J; Jones L; Greene N; Wager T
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):921-31. PubMed ID: 19519283
[TBL] [Abstract][Full Text] [Related]
5. Modeling promiscuity based on in vitro safety pharmacology profiling data.
Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
[TBL] [Abstract][Full Text] [Related]
6. Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects.
Klekota J; Brauner E; Roth FP; Schreiber SL
J Chem Inf Model; 2006; 46(4):1549-62. PubMed ID: 16859287
[TBL] [Abstract][Full Text] [Related]
7. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
Dimova D; Hu Y; Bajorath J
J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
[TBL] [Abstract][Full Text] [Related]
8. Activity profile relationships between structurally similar promiscuous compounds.
Hu Y; Bajorath J
Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
[TBL] [Abstract][Full Text] [Related]
9. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
10. Compound promiscuity: what can we learn from current data?
Hu Y; Bajorath J
Drug Discov Today; 2013 Jul; 18(13-14):644-50. PubMed ID: 23524195
[TBL] [Abstract][Full Text] [Related]
11. Drug- and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers.
Chuprina A; Lukin O; Demoiseaux R; Buzko A; Shivanyuk A
J Chem Inf Model; 2010 Apr; 50(4):470-9. PubMed ID: 20297844
[TBL] [Abstract][Full Text] [Related]
12. Safety screening in early drug discovery: An optimized assay panel.
Bendels S; Bissantz C; Fasching B; Gerebtzoff G; Guba W; Kansy M; Migeon J; Mohr S; Peters JU; Tillier F; Wyler R; Lerner C; Kramer C; Richter H; Roberts S
J Pharmacol Toxicol Methods; 2019; 99():106609. PubMed ID: 31284073
[TBL] [Abstract][Full Text] [Related]
13. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography.
Guiffant D; Tribouillard D; Gug F; Galons H; Meijer L; Blondel M; Bach S
Biotechnol J; 2007 Jan; 2(1):68-75. PubMed ID: 17225251
[TBL] [Abstract][Full Text] [Related]
14. Chemogenomic analysis of safety profiling data.
Scheiber J; Jenkins JL
Methods Mol Biol; 2009; 575():207-23. PubMed ID: 19727617
[TBL] [Abstract][Full Text] [Related]
15. Revealing promiscuous drug-target interactions by chemical proteomics.
Bantscheff M; Scholten A; Heck AJ
Drug Discov Today; 2009 Nov; 14(21-22):1021-9. PubMed ID: 19596079
[TBL] [Abstract][Full Text] [Related]
16. PASS: identification of probable targets and mechanisms of toxicity.
Poroikov V; Filimonov D; Lagunin A; Gloriozova T; Zakharov A
SAR QSAR Environ Res; 2007; 18(1-2):101-10. PubMed ID: 17365962
[TBL] [Abstract][Full Text] [Related]
17. Rational application of drug promiscuity in medicinal chemistry.
Mei Y; Yang B
Future Med Chem; 2018 Aug; 10(15):1835-1851. PubMed ID: 30019924
[TBL] [Abstract][Full Text] [Related]
18. Clustering and its application in multi-target prediction.
Liu W; Johnson DE
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):98-107. PubMed ID: 19152218
[TBL] [Abstract][Full Text] [Related]
19. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
Beaumont K; Smith DA
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
[TBL] [Abstract][Full Text] [Related]
20. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs.
Perola E
J Med Chem; 2010 Apr; 53(7):2986-97. PubMed ID: 20235539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
